MAP2K1 and melanoma: There are a series of mechanisms described that underlie the secondary resistance of BRAF-mutant melanomas that occur after BRAF inhibitor treatment, including NRAS mutations, aberrant BRAF splicing, BRAF amplifications, MAP2K1 (MEK1) mutations, PTEN and PIK3CA mutations, and COT1 overexpression [6, 7].